About Us
Our Story
Team
Careers
News
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Select specialty
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Oncology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Primary Care
Psychiatry
Pulmonology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Confirm Password
CAR T and NK Cell Therapy in Myeloma
By
Parameswaran Hari
5 Videos
August 6, 2018
1 Comment
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
The O'Neal Comprehensive Cancer Center at UAB
UAB Hematology Review 2021
Fri, Mar 5, 2021
22:47
UChicago CAR T-Cell Symposium 2019
Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussion…
Feat.
M. Leukam
23:48
UChicago CAR T-Cell Symposium 2019
2019 Update on CAR-T in Multiple Myeloma - Can We Improve Upon These Res...
Feat.
J. Jasielec
06:21
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier in ...
Feat.
F. Anwer
27:06
UChicago CAR T-Cell Symposium 2019
Why Does CAR T-Cell Therapy Fail? An Update on Mechanisms of Resistance/Re…
Feat.
J. Kline
15:02
Krina Patel
Clinical Trials in Myeloma in 2018
07:57
Penn Medicine 2020 Updates in Oncology
ASCO Update on Myeloma: How Promising Are BCMA CAR-T & BCMA x CD3 Bispec...
Feat.
D. Vogl
15:47
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Myeloma State of the Art Update: Bone Disease, MRD Assessment, How to Mana…
Feat.
S. Lonial
15:31
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
ASH 2019 Relapsed Myeloma Highlights: Can Biomarkers Predict Response to...
Feat.
A. Rosko
07:23
Indy Hematology Review
Novel Immune Therapies in Myeloma: BCMA Immunotoxin, Bites, and CAR T cells
Feat.
K. Anderson
27:01
SOHO Italy 1st School of Multiple Myeloma
Europe vs. USA Experience in MM: Access to New Drugs (Off-Label vs Approve…
Feat.
K. Anderson
12:32
Indy Hematology Review
What's New in Immunotherapy and Genomics in Multiple Myeloma?
Feat.
K. Anderson
15:10
Krina Patel
Developing CAR T-cells in Multiple Myeloma
13:30
Helen Heslop
CAR T-cell Therapy for Hematologic Malignancies Other Than CD19
14:43
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
What Will The Future Hold for Myeloma Treatment CARTs vs BiTES?
Feat.
R. Orlowski
09:46
2018 Pan Pacific Lymphoma Conference
CAR T-cell Toxicities and Team Management
Feat.
S. Blumel
10:38
Krina Patel
How Do We Make Responses Durable in Multiple Myeloma?
17:44
UChicago CAR T-Cell Symposium 2019
Current Grading and Management Strategies of CAR-T Toxicities: Cytokine Re…
Feat.
S. Kosuri
06:41
UChicago CAR T-Cell Symposium 2019
Mechanisms of Acquired CAR-T Cell Resistance: Is There a 'Best' in Produ...
Feat.
J. Labelle
22:21
UChicago CAR T-Cell Symposium 2019
Immune Regulation and Chimeric Antigen Receptor (CAR) T-Cell Therapy: Me...
Feat.
J. Labelle
26:41
Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient
BCMA - Based Immunotherapy for Myeloma: Belantamab Mafodotin, CAR-T Cells …
Feat.
A. Cohen